/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Amgen Inc. (AMGN), headquartered in Thousand Oaks, California, is a renowned player in the biotechnology industry. Valued at $163.62 billion by market cap, the company uses technology and human genetic data to discover, develop, manufacture, and deliver innovative medicine.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and AMGN fits right into that category. For more than 40 years, AMGN has been one of the leading players in using living cells to make biological medicines. The company is advancing a broad and deep pipeline that builds on its existing portfolio of drugs to treat cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases.